DYRK1B and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting DYRK1B provides a new rationale for treatment of various solid cancers such as liposarcoma or breast cancers (reviews: [116,117]) as well as in chronic myeloid leukemia (CML).